Qiagen (QGEN) Aktievy
Qiagen N.V. tillhandahåller lösningar för att omvandla biologiska prover till molekylära insikter över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 2/6 |
QGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Qiagen N.V. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$40.57 |
| 52 veckors högsta | US$57.82 |
| 52 veckors lägsta | US$32.53 |
| Beta | 0.64 |
| 1 månads förändring | 11.82% |
| 3 månaders förändring | 6.85% |
| 1 års förändring | -23.53% |
| 3 års förändring | -23.06% |
| 5 års förändring | -29.59% |
| Förändring sedan börsintroduktionen | 1,751.27% |
Senaste nyheter och uppdateringar
Seeking Alpha • Jul 12
Qiagen: New Launches Signal A Turnaround
Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 09
QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook
Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.Recent updates
Seeking Alpha • Jul 12
Qiagen: New Launches Signal A Turnaround
Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 09
QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook
Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.
Uppdatering av berättelse • Jun 25
QGEN: Expect Post Pandemic Testing Demand To Support Oncology And Diagnostics Expansion
Analysts have adjusted the fair value estimate for Qiagen slightly higher to $43.96 from $43.82, reflecting a modestly higher discount rate, alongside mixed recent price target moves that highlight both concerns over growth in areas like QuantiFERON and renewed interest in the stock as a potential structural beneficiary of post pandemic demand trends. Analyst Commentary Recent Street research on Qiagen reflects a split view, with some bullish analysts pointing to potential growth opportunities and valuation support, while more cautious analysts focus on execution risks and reduced expectations in key product areas.Analysartikel • Jun 21
Qiagen (QGEN) Stock Could Be 15.7% Undervalued After QIAcuity Expansion
Qiagen (NYSE:QGEN) is in focus after announcing new additions to its QIAcuity digital PCR ecosystem, including expanded gene expression tools, higher multiplexing and upgraded software and automation for high throughput labs. See our latest analysis for Qiagen. The QIAcuity update comes as Qiagen’s share price has shown mixed momentum, with a 1-month share price return of 5.06%, a year-to-date share price return that is down 22.32%, and a 5-year total shareholder return that is down 23.67%...Uppdatering av berättelse • Jun 06
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds
Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.
Ny berättelse • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?Ny berättelse • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.Uppdatering av berättelse • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.Uppdatering av berättelse • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.Uppdatering av berättelse • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.Uppdatering av berättelse • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.Uppdatering av berättelse • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.Uppdatering av berättelse • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Uppdatering av berättelse • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).Analysartikel • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...Uppdatering av berättelse • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.Uppdatering av berättelse • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.Uppdatering av berättelse • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.Analysartikel • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...Uppdatering av berättelse • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.Uppdatering av berättelse • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.Uppdatering av berättelse • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.Uppdatering av berättelse • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.Analysartikel • Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...Analysartikel • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...Analysartikel • Aug 05
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...Seeking Alpha • Feb 25
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking AlphaAktieägarnas avkastning
| QGEN | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | -1.6% | -3.9% | -0.7% |
| 1Y | -23.5% | 14.8% | 17.3% |
Avkastning vs industri: QGEN presterade sämre än US Life Sciences branschen som gav 14.8 % under det senaste året.
Avkastning vs Marknaden: QGEN presterade sämre än US marknaden som gav 17.3 % under det senaste året.
Prisvolatilitet
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: QGEN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: QGEN s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1984 | 5,500 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. tillhandahåller lösningar för att omvandla biologiska prover till molekylära insikter över hela världen. Företaget erbjuder förbrukningsvaror för provteknik, t.ex. kit för stabilisering och rening av nukleinsyror för provmaterial, manuell och automatiserad bearbetning för genotypning, genuttryck och virus- och bakterieanalys samt kiseldioxidmembran och magnetiska pärlor; förbrukningsvaror för sekundär provteknik, inklusive kit och komponenter för rening av nukleinsyror; samt instrument för rening av nukleinsyror, kvalitetskontroll och tillbehör. Företaget tillhandahåller också förbrukningsvaror för immunförsvar, t.ex. interferon-gamma release assay för TB-testning, och assays för post-transplantationstestning och övervakning av virusbelastning; förbrukningsvaror för onkologi och sexuell och reproduktiv hälsa, inklusive assays för prenatal testning och upptäckt av sexuellt överförbara sjukdomar och HPV; assays för analys av genomiska varianter; och instrument för sample to insight, inklusive molekylär analys i ett steg av svårdiagnostiserade syndrom och integrerad PCR-testning.
Qiagen N.V. Sammanfattning av grunderna
| QGEN grundläggande statistik | |
|---|---|
| Börsvärde | US$8.38b |
| Vinst(TTM) | US$402.17m |
| Intäkter(TTM) | US$2.10b |
20.9x
P/E-förhållande4.0x
P/S-förhållandeÄr QGEN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| QGEN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$2.10b |
| Kostnad för intäkter | US$710.57m |
| Bruttovinst | US$1.39b |
| Övriga kostnader | US$986.13m |
| Intäkter | US$402.17m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 05, 2026
| Vinst per aktie (EPS) | 1.94 |
| Bruttomarginal | 66.15% |
| Nettovinstmarginal | 19.16% |
| Skuld/egenkapitalförhållande | 50.0% |
Hur har QGEN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
5.9%
Aktuell utdelningsavkastning0%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/22 23:08 |
| Aktiekurs vid dagens slut | 2026/07/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Qiagen N.V. bevakas av 40 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |